Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (151-160 of 214) with videos related to

Pageof 22
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|December 21, 2018
Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis CJia Li, Stuart C Gordon, Loralee B Rupp, et al.
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2013
Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US populationStuart C Gordon, Lois E Lamerato, Loralee B Rupp, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 26, 2016
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV InfectionMei Lu, Jia Li, Talan Zhang, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison, Bruce R Bacon, Stuart C Gordon, et al.
Journal of Viral Hepatitis|March 31, 2016
Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinomaMei Lu, Jia Li, Loralee B Rupp, et al.
Digestive Diseases and Sciences|July 18, 2014
Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identificationMei Lu, Loralee B Rupp, Anne C Moorman, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Pageof 22

Showing results (151-160 of 214) with videos related to

Sort By:
Pageof 22
Liver International : Official Journal of the International Association for the Study of the Liver|December 21, 2018
Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis CJia Li, Stuart C Gordon, Loralee B Rupp, et al.
Journal of Hepatology|September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGETStuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2013
Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US populationStuart C Gordon, Lois E Lamerato, Loralee B Rupp, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 26, 2016
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV InfectionMei Lu, Jia Li, Talan Zhang, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison, Bruce R Bacon, Stuart C Gordon, et al.
Journal of Viral Hepatitis|March 31, 2016
Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinomaMei Lu, Jia Li, Loralee B Rupp, et al.
Digestive Diseases and Sciences|July 18, 2014
Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identificationMei Lu, Loralee B Rupp, Anne C Moorman, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Pageof 22